ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0703

Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis

Alicia Rodriguez-Pla, Sierra Pacific Arthritis and Rheumatology Centers, Fresno, CA

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, gender, giant cell arteritis, Granulomatosis with Polyangiitis (GPA), Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients with the most common subtypes of primary systemic vasculitides. We aimed to estimate the scope of cardiovascular-related death in patients with primary systemic vasculitis in the United States in recent years.

Methods: We used the CDC Wonder Multiple Causes of Death database and its query system. All deaths related to cardiovascular disease (CVD) as the UCD, and primary systemic vasculitides as CCDs were included from January 1, 1999, to December 31, 2020. We used the ICD-10 code I00-I99 (Diseases of the circulatory system) as the UCD, and the ICD-10 codes of the different subtypes of the primary systemic vasculitides were grouped as CCDs. Diseases of the circulatory system and all grouped vasculitides were initially queried separately, and the 2 disorders were also queried together to find out the mortality rates of CVD as UCD and vasculitis as CCD. We also performed the analysis by vasculitis subtypes. We obtained mortality rates by year, gender, race, and state. To obtain age-adjusted mortality rates we used the year 2000 U.S. standard population. We show mortality rates as the number of deaths per 100,000 for CVD, and per million for vasculitis. We applied a linear regression model to evaluate trends over time.

Results: During the 22-year period, CVD was the UCD of death of 18,783,791 patients. The age-adjusted mortality rate was 254.38 per 100,000 (95% CI: 254.27-254.50). For vasculitis as CCD, there were 29,229 deaths, and the age-adjusted mortality rate was 4.02 per 1,000,000 (95% CI: 3.97-4.07). When CVD as UCD and vasculitis as CCD were combined, there were 6,042 deaths, with an age-adjusted rate of 0.82 per 1,000,000 (95% CI: 0.80-0.84). Since 1999, there has been a significant trend to the decrease (p< 0.0001) (Figure 1). The age-adjusted mortality rate was higher in females than in males (0.88 vs. 0.71 per million). The percentage of females was 64.5%. The age-adjusted mortality rate was higher in Whites (0.90, 0.87-0.92) than in Blacks (0.39, 0.34-0.44) (Table 1). The percentage of Whites was 93.4%. M31.6 (Other giant cell arteritis) accounted for 58% of all vasculitis deaths. There was differential geographic distribution in the mortality rates by state. The states with the highest age-adjusted mortality rates were Maine, Vermont, Oregon, Iowa, and Minnesota (Table 2). The states with the lowest rates were Louisiana, Nevada, Mississippi, Florida, and Georgia.

Conclusion: There has been a progressive decrease in mortality rates in recent years. Contrary to what is found in the general population, in our study, the age-adjusted mortality rates were higher in females and in Whites. This can be explained, at least in part, by the fact that vasculitides are more frequent in Whites, and GCA, which is the subtype of vasculitis associated with the highest mortality rate in our study, is more frequent in white females. Mortality rates of vasculitis are more frequent in northern states. Investigation of the reasons for the geographic disparities is warranted. Our findings should be taken with caution until quality studies to determine the reliability of the data about these rare diseases available in national databases are performed.

Supporting image 1

Figure 1. Age-adjusted mortality rate for cardiovascular as the underlying cause of death and with vasculitis as contributing cause of death, by year.

Supporting image 2

Table 1. Age-adjusted mortality rate per million for cardiovascular disease as underlying cause of death and vasculitis as contributing cause of death, by race and gender.

Supporting image 3

Table 2. The 12 states with the highest mortality due to cardiovascular disease as underlying cause of death and vasculitis as contributing cause of death, with age-adjusted rates and 95% confidence interval.


Disclosures: A. Rodriguez-Pla: None.

To cite this abstract in AMA style:

Rodriguez-Pla A. Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-disease-related-mortality-in-primary-systemic-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-disease-related-mortality-in-primary-systemic-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology